Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Revenue (2017 - 2025)

Crinetics Pharmaceuticals has reported Revenue over the past 9 years, most recently at $6.2 million for Q4 2025.

  • For Q4 2025, Revenue changed N/A year-over-year to $6.2 million; the TTM value through Dec 2025 reached $7.7 million, up 640.71%, while the annual FY2025 figure was $7.7 million, 640.71% up from the prior year.
  • Revenue for Q4 2025 was $6.2 million at Crinetics Pharmaceuticals, up from $143000.0 in the prior quarter.
  • Over five years, Revenue peaked at $6.2 million in Q4 2025 and troughed at $143000.0 in Q3 2025.
  • A 5-year average of $1.3 million and a median of $674500.0 in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: crashed 76.11% in 2024 and later soared 158.4% in 2025.
  • Year by year, Revenue stood at $1.1 million in 2021, then crashed by 34.23% to $709000.0 in 2022, then plummeted by 51.2% to $346000.0 in 2023, then rose by 15.32% to $399000.0 in 2024, then surged by 1444.11% to $6.2 million in 2025.
  • Business Quant data shows Revenue for CRNX at $6.2 million in Q4 2025, $143000.0 in Q3 2025, and $1.0 million in Q2 2025.